Study Identifies Disparity in Survival of AYA Hodgkin Lymphoma
Mortality in adolescent and young adult Hodgkin lymphoma patients is significantly affected by ethnic and socioeconomic factors, as well as insurance status, according to a new study published in Cancer Epidemiology, Biomarkers & Prevention.
Does Geographic Location Influence Healthcare Utilization in Children With Lymphoma?
A study presented at the 57th meeting of the American Society of Hematology finds that distance from the site of care could could adversely affect outcomes in children with acute lymphoblastic leukemia and acute myeloid leukemia.
Healthcare Utilization in Children With Sickle Cell Disease
At the annual meeting of the American Society of Hematology, researchers from the Aflac Cancer and Blood Disorders Center presented analysis evaluating the factors that influence health outcomes in children with sickle cell disease.
Study Shows Academic Hospitals Better at Caring for ALL Patients
A study presented during a health outcomes session at the American Society of Hematology meeting evaluated the difference in overall survival in patients with acute lymphoblastic leukemia treated in academic versus nonacademic hospitals.
Insurance Status Determines OS in Patients With CML
Results presented at the annual meeting of the American Society of Hematology found that many patients diagnosed with chronic myeloid leukemia may not have access to or receive appropriate care, in part due to their insurance coverage.
Importance of Patient-Reported Outcomes and Quality-of-Life Measures in Myeloid Disease
Results from a patient-reported outcomes measure of symptoms and symptom burden, experienced by patients with acute myeloid leukemia and myelodysplastic syndrome, were presented at the 57th annual meeting of the American Society of Hematology.
Smoking Can Reduce Survival of Breast Cancer Patients
A study published in the Journal of Clinical Oncology has found that smoking before and after diagnosis of breast cancer is associated with increased mortality from breast cancer as well as other conditions, including respiratory and cardiovascular disease.
Amgen Submits BLA for Adalimumab Biosimilar Despite Patent Battles
The Biologics License Application for the tumor necrosis factor alpha blocker, ABP 501, was submitted following results from a phase 3 study in 500 patients with moderate to severe plaque psoriasis and rheumatoid arthritis.
How Do You Develop, and Successfully Incorporate, PROs in Hematology? Experts Chime in at ASH
An educational session on Patient-Reported Outcomes in Hematology at the annual meeting of the American Society of Hematology, discussed the importance of embracing the patient perspective in healthcare delivery.
Experts Share Concepts of Quality Measures and Pay-for-Performance With Hematologists
At the annual meeting of the American Society of Hematology, experts discussed quality measurement, public performance reporting, and pay-for-performance and it's impact on healthcare in the United States.
Abundant Optimism at the ASH/FDA Joint Symposium on New Drug Approvals in Multiple Myeloma
At a joint session at the annual meeting of the American Society of Hematology, primary clinical reviewers from the FDA discussed the safety and efficacy issues of 3 very recently approved drugs for multiple myeloma, along with 2 clinicians who have extensive experience with these drugs in the real-world setting.
New Hematology Drugs: Progress and Challenges Discussed at the 57th ASH Meeting
A session on the first day of the annual meeting of the American Society of Hematology, held December 5-8, 2015, in Orlando, Florida, clinicians discussed the promise and challenges of using newly approved hematology/oncology agents.
Study Narrows Time to Surgery Following Chemoradiotherapy in Rectal Cancer
A retrospective analysis of data from the National Cancer Data Base has found that patients who had cancer surgery at 56 days after the end of combined chemoradiotherapy presented with the best overall survival and successful removal of their residual tumors.